Sanofi Respiratory Deal History & Licensing Activity
Sanofi Respiratory is a large pharma headquartered in France. Over the past three years, Sanofi Respiratory has been involved in 8 licensing and acquisition transactions, with a primary focus on Small Molecules (7 deals).
Deals (12mo)
5
Active Trials
20
Top Modality
Small Molecules
Focus Area
Immunology
Sanofi Respiratory Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Sanofi Respiratory in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| rovadicitinib | Sanofi | Small Molecules | Unknown | license | Jul 1, 2026 |
| rovadicitinib | Sanofi | Small Molecules | Unknown | license | Jun 27, 2026 |
| AXPAXLI | Sanofi | Other | Phase 3 | acquisition | Mar 31, 2026 |
| rovadicitinib | Sanofi | Small Molecules | Unknown | license | Mar 15, 2026 |
| Undisclosed | Sanofi | Bispecific Antibodies | Discovery | collaboration | Jan 5, 2026 |
Sanofi Respiratory Pipeline Focus
Therapeutic areas and modalities where Sanofi Respiratory is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Sanofi Respiratory Strategic Signals
Key indicators of Sanofi Respiratory's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Sanofi Respiratory's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Immunology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Ophthalmology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for ophthalmology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Sanofi Respiratory Licensing & Deal Activity
Sanofi Respiratory is a large pharma company based in France that has been actively engaged in licensing transactions across the biopharma landscape. With 8 deals over the past three years, Sanofi Respiratory ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Sanofi Respiratory include Immunology (5 deals and trials), Mega Deals (4 deals and trials), Ophthalmology (2 deals and trials), and Infectious Disease (1 deal and trial). In terms of modality, Sanofi Respiratory has shown particular interest in small molecules, bispecific antibodies, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Sanofi Respiratory and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Sanofi Respiratory's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.